Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours

Melphalan proved to be active in up-front treatment at non-myeloablative doses, and its toxicity was predictable and manageable. The schedule adopted did not interfere with any further intensive chemotherapy or myeloablative treatment in the majority of cases.